<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25449931</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>11</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1998-3689</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>62</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Indian journal of ophthalmology</Title>
          <ISOAbbreviation>Indian J Ophthalmol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ocular myasthenia gravis: a review.</ArticleTitle>
        <Pagination>
          <StartPage>985</StartPage>
          <EndPage>991</EndPage>
          <MedlinePgn>985-91</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.4103/0301-4738.145987</ELocationID>
        <Abstract>
          <AbstractText>Myasthenia gravis (MG) is a disease that affects the neuro-muscular junction resulting in classical symptoms of variable muscle weakness and fatigability. It is called the great masquerader owing to its varied clinical presentations. Very often, a patient of MG may present to the ophthalmologist given that a large proportion of patients with systemic myasthenia have ocular involvement either at presentation or during the later course of the disease. The treatment of ocular MG involves both the neurologist and ophthalmologist. Thus, the aim of this review was to highlight the current diagnosis, investigations, and treatment of ocular MG.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nair</LastName>
            <ForeName>Akshay Gopinathan</ForeName>
            <Initials>AG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patil-Chhablani</LastName>
            <ForeName>Preeti</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Strabismus and Neuro-Ophthalmology, Jasti V Ramanamma Children's Eye Care Centre, Hyderabad, Telangana, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Venkatramani</LastName>
            <ForeName>Devendra V</ForeName>
            <Initials>DV</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gandhi</LastName>
            <ForeName>Rashmin Anilkumar</ForeName>
            <Initials>RA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Indian J Ophthalmol</MedlineTA>
        <NlmUniqueID>0405376</NlmUniqueID>
        <ISSNLinking>0301-4738</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019468" MajorTopicYN="Y">Disease Management</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009017" MajorTopicYN="N">Morbidity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009157" MajorTopicYN="Y">Myasthenia Gravis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Conflict of Interest:</b> None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25449931</ArticleId>
        <ArticleId IdType="pmc">PMC4278125</ArticleId>
        <ArticleId IdType="doi">10.4103/0301-4738.145987</ArticleId>
        <ArticleId IdType="pii">IndianJOphthalmol_2014_62_10_985_145987</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: Past, present, and future. J Clin Invest. 2006;116:2843–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1626141</ArticleId>
            <ArticleId IdType="pubmed">17080188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Brien MD. The miracle at St Alfege's: Seventy years on. J R Soc Med. 2007;100:257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1885387</ArticleId>
            <ArticleId IdType="pubmed">17541091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>López-Cano M, Ponseti-Bosch JM, Espin-Basany E, Sánchez-García JL, Armengol-Carrasco M. Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis. Ann Thorac Surg. 2003;76:1643–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14602301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singhal BS, Bhatia NS, Umesh T, Menon S. Myasthenia gravis: A study from India. Neurol India. 2008;56:352–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18974563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grigg J. Extraocular muscles: Relationship of structure and function to disease. Aust N Z J Ophthalmol. 1999;27:369–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10641892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sommer N, Melms A, Weller M, Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects. Doc Ophthalmol. 1993;84:309–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8156854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonio-Santos AA, Eggenberger ER. Medical treatment options for ocular myasthenia gravis. Curr Opin Ophthalmol. 2008;19:468–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18854691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci. 1987;505:472–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3318620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oosterhuis HJ. Observations of the natural history of myasthenia gravis and the effect of thymectomy. Ann N Y Acad Sci. 1981;377:678–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6951492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keane JR. Vertical diplopia. Semin Neurol. 1986;6:147–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3332419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaminski HJ, Maas E, Spiegel P, Ruff RL. Why are eye muscles frequently involved in myasthenia gravis? Neurology. 1990;40:1663–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1700335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finelli PF, Hoyt WF. Myasthenic abduction mystagmus in a patient with hyperthyroidism. Neurology. 1976;26(6 PT 1):589–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">945502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yee RD, Cogan DG, Zee DS, Baloh RW, Honrubia V. Rapid eye movements in myasthenia gravis. II. Electro-oculographic analysis. Arch Ophthalmol. 1976;94:1465–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">962656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sethi KD, Rivner MH, Swift TR. Ice pack test for myasthenia gravis. Neurology. 1987;37:1383–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3614664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lepore FE, Sanborn GE, Slevin JT. Pupillary dysfunction in myasthenia gravis. Ann Neurol. 1979;6:29–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">228589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamazaki A, Ishikawa S. Abnormal pupillary responses in myasthenia gravis. A pupillographic study. Br J Ophthalmol. 1976;60:575–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1042752</ArticleId>
            <ArticleId IdType="pubmed">974056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manson N, Stern G. Defects of near vision in myasthenia gravis. Lancet. 1965;1:935–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14275711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hubbard JI, Jones SF, Landau EM. The effect of temperature change upon transmitter release, facilitation and post-tetanic potentiation. J Physiol. 1971;216:591–609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1331924</ArticleId>
            <ArticleId IdType="pubmed">4327694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kearsey C, Fernando P, D’Costa D, Ferdinand P. The use of the ice pack test in myasthenia gravis. JRSM Short Rep. 2010;1:14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2984327</ArticleId>
            <ArticleId IdType="pubmed">21103106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubis KC, Danesh-Meyer HV, Savino PJ, Sergott RC. The ice test versus the rest test in myasthenia gravis. Ophthalmology. 2000;107:1995–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11054320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chatzistefanou KI, Kouris T, Iliakis E, Piaditis G, Tagaris G, Katsikeris N, et al.  The ice pack test in the differential diagnosis of myasthenic diplopia. Ophthalmology. 2009;116:2236–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19744729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellis FD, Hoyt CS, Ellis FJ, Jeffery AR, Sondhi N. Extraocular muscle responses to orbital cooling (ice test) for ocular myasthenia gravis diagnosis. J AAPOS. 2000;4:271–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11040476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barton JJ, Fouladvand M. Ocular aspects of myasthenia gravis. Semin Neurol. 2000;20:7–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10874773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phillips LH, 2nd, Melnick PA. Diagnosis of myasthenia gravis in the 1990s. Semin Neurol. 1990;10:62–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2189182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly JJ, Jr, Daube JR, Lennon VA, Howard FM, Jr, Younge BR. The laboratory diagnosis of mild myasthenia gravis. Ann Neurol. 1982;12:238–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7137958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JY, Park KD, Richman DP. Treatment of myasthenia gravis based on its immunopathogenesis. J Clin Neurol. 2011;7:173–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3259491</ArticleId>
            <ArticleId IdType="pubmed">22259613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nastuk WL, Kessler HJ, Grynbaum A, Smith M, Herrmann C., Jr Immunological changes following thymectomy in myasthenia gravis. Arch Neurol. 1966;15:1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5328325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strauss AJ, Kemp PG, Douglas SD. Myasthenia gravis. Lancet. 1966;1:772–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4159740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katzberg HD, Bril V. A comparison of electrodiagnostic tests in ocular myasthenia gravis. J Clin Neuromuscul Dis. 2005;6:109–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19078758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2:44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2211463</ArticleId>
            <ArticleId IdType="pubmed">17986328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozdemir C, Young RR. The results to be expected from electrical testing in the diagnosis of myasthenia gravis. Ann N Y Acad Sci. 1976;274:203–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1066987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa J, Evangelista T, Conceição I, de Carvalho M. Repetitive nerve stimulation in myasthenia gravis – relative sensitivity of different muscles. Clin Neurophysiol. 2004;115:2776–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15546785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodríguez J, Dimitrova NA, Dimitrov GV, Gila L. Shape variability of potentials recorded by a single-fiber electrode and its effect on jitter estimation. Ann Biomed Eng. 2011;39:812–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21108004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padua L, Stalberg E, LoMonaco M, Evoli A, Batocchi A, Tonali P. SFEMG in ocular myasthenia gravis diagnosis. Clin Neurophysiol. 2000;111:1203–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10880794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanders DB, Howard JF.  Disorders of neuromuscular transmission. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, editors. Neurology in Clinical Practice. 1st ed. Boston: Butterworth-Heine-Mann; 1991. pp. 1819–42.</Citation>
        </Reference>
        <Reference>
          <Citation>Osserman KE, Tsairis P, Weiner LB. Myasthenia gravis and thyroid disease: Clinical and immunologic correlation. J Mt Sinai Hosp N Y. 1967;34:469–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5234931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen CS, Lee AW, Miller NR, Lee AG. Double vision in a patient with thyroid disease: What's the big deal? Surv Ophthalmol. 2007;52:434–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17574067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gandhi RA, Nair AG.  Ocular myasthenia gravis. In: Chaudhari Z, Vanathi M, editors. Postgraduate Ophthalmology. New Delhi: Jaypee Brothers Medical Publishers; 2011. pp. 1510–21.</Citation>
        </Reference>
        <Reference>
          <Citation>Schlezinger NS, Fairfax WA. Evaluation of ocular signs and symptoms in myasthenia gravis. Arch Ophthalmol. 1959;62:985–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14442895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60:243–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12580710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kupersmith MJ, Moster M, Bhuiyan S, Warren F, Weinberg H. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol. 1996;53:802–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8759987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: Report of 116 patients. Ann Neurol. 1984;15:291–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6721451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, et al.  Ocular myasthenia gravis: Response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997;62:156–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC486727</ArticleId>
            <ArticleId IdType="pubmed">9048716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004;217:131–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14706214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mee J, Paine M, Byrne E, King J, Reardon K, O’Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003;23:251–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14663303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kupersmith MJ. Ocular myasthenia gravis: Treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256:1314–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19377863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50:1778–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9633727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: Diagnosis and follow-up of 100 consecutive patients. J Neurol. 1997;244:112–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9120493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8357194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316:719–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3547126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan JW. Mycophenolate mofetil for ocular myasthenia. J Neurol. 2008;255:510–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18299952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71:394–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18434639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, et al.  An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71:400–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18434638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schumacher CH, Roth P. ThymektomiebeieinemFall von Morbus Basedowimit Myasthenie. Mitt Grenzgeb Med Chirurgia. 1912;25:746–65.</Citation>
        </Reference>
        <Reference>
          <Citation>Blalock A, Mason MF, Morgan HJ, Riven SS. Myasthenia gravis and tumors of the thymic region: Report of a case in which the tumor was removed. Ann Surg. 1939;110:544–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1391425</ArticleId>
            <ArticleId IdType="pubmed">17857470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evoli A, Batocchi AP, Provenzano C, Ricci E, Tonali P. Thymectomy in the treatment of myasthenia gravis: Report of 247 patients. J Neurol. 1988;235:272–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3385443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hatton PD, Diehl JT, Daly BD, Rheinlander HF, Johnson H, Schrader JB, et al.  Transsternal radical thymectomy for myasthenia gravis: A 15-year review. Ann Thorac Surg. 1989;47:838–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2757437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buckingham JM, Howard FM, Jr, Bernatz PE, Payne WS, Harrison EG, Jr, O’Brien PC, et al.  The value of thymectomy in myasthenia gravis: A computer-assisted matched study. Ann Surg. 1976;184:453–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1345441</ArticleId>
            <ArticleId IdType="pubmed">1015890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez M, Gomez MR, Howard FM, Jr, Taylor WF. Myasthenia gravis in children: Long-term follow-up. Ann Neurol. 1983;13:504–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6870202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olanow CW, Wechsler AS, Roses AD. A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis. Ann Surg. 1982;196:113–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1352464</ArticleId>
            <ArticleId IdType="pubmed">7092360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts PF, Venuta F, Rendina E, De Giacomo T, Coloni GF, Follette DM, et al.  Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg. 2001;122:562–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11547310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schumm F, Wiethölter H, Fateh-Moghadam A, Dichgans J. Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry. 1985;48:332–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1028297</ArticleId>
            <ArticleId IdType="pubmed">3998738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodsky MC, Baker RS, Hamed LM.  New York: Springer; 1996. Pediatric Neuro-ophthalmology; pp. 251–301.</Citation>
        </Reference>
        <Reference>
          <Citation>Mullaney P, Vajsar J, Smith R, Buncic JR. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. Ophthalmology. 2000;107:504–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10711889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Middleton LT. Congenital myasthenic syndromes 34th ENMC International Workshop, 10-11 June 1995. Neuromuscul Disord. 1996;6:133–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8664566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ortiz S, Borchert M. Long-term outcomes of pediatric ocular myasthenia gravis. Ophthalmology. 2008;115:1245–48.e1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18155768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pineles SL, Avery RA, Moss HE, Finkel R, Blinman T, Kaiser L, et al.  Visual and systemic outcomes in pediatric ocular myasthenia gravis. Am J Ophthalmol. 2010;150:453–9.e3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20678749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gadient P, Bolton J, Puri V. Juvenile myasthenia gravis: Three case reports and a literature review. J Child Neurol. 2009;24:584–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19406758</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
